Consensus ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
9.75 ^USD	+3.07%		+16.77%	+77.92%

Apr. 30	ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	CI
Apr. 30	Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	CI

Evolution of the average Target Price on ARS Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

093ad5d713cc373d6c8d.82pUde-p8dJtoUewKbPKMWANq-1HAOrBfVuPBQZuN_k.khAGE6TwpoUB8jDRQ_avATVEkoUhVpy2LR_kUlkAXsucPSFHq8614SHHFg~38a80cb2b0dbc763f8cc12eb15001158

Analyst Recommendations on ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18	MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18	MT
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	Apr. 10	MT
Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6	Mar. 05	MT
William Blair Upgrades ARS Pharmaceuticals to Outperform From Market Perform	Feb. 20	MT
Wedbush Raises ARS Pharmaceuticals' PT to $19 From $13 After Model Adjustments, Keeps Outperform Rating	Feb. 06	MT
Wedbush Raises ARS Pharmaceuticals' PT to $13 From $5, Says Market Opportunity Intact; Maintains Outperform Rating	Nov. 13	MT
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	23-09-20	MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision	23-09-20	MT
Rate Hike Pause Hopes Boost Exchange-Traded Funds, Equity Futures Premarket Wednesday	23-09-20	MT
William Blair Downgrades ARS Pharmaceuticals to Market Perform From Outperform	23-09-20	MT
Wedbush Trims ARS Pharmaceuticals' PT to $15 From $17, Adjusts US, EU Launch Estimates, Lowers Peak Penetration for neffy/Anaphylaxis in US; Keeps Outperform Rating	23-06-21	MT
Wedbush Initiates ARS Pharmaceuticals at Outperform With $10 PT, Says Neffy Intranasal Spray Set to Shake Up Epinephrine Market	23-01-31	MT
William Blair Initiates ARS Pharmaceuticals With Outperform	23-01-04	MT
SVB Securities Initiates ARS Pharmaceuticals With Outperform Rating, Price Target is $14	22-12-13	MT
Stifel Adjusts Price Target on Silverback Therapeutics to $5 From $6, Reiterates Hold Rating	22-05-16	MT
Goldman Sachs Downgrades Silverback Therapeutics to Neutral From Buy, Adjusts Price Target to $3.50 From $25	22-04-04	MT
JonesTrading Downgrades Silverback Therapeutics to Hold From Buy	22-04-01	MT
SVB Leerink Downgrades Silverback Therapeutics to Market Perform from Outperform, Adjusts Price Target to $1.80 from $25	22-04-01	MT
HC Wainwright Downgrades Silverback Therapeutics to Neutral from Buy	22-04-01	MT
Stifel Downgrades Silverback Therapeutics to Hold from Buy, Adjusts Price Target to $6 from $32	22-04-01	MT
SVB Leerink Adjusts Silverback Therapeutics' Price Target to $25 From $42, Keeps Outperform Rating	21-11-12	MT
SILVERBACK THERAPEUTICS : SVB Leerink Adjusts Silverback Therapeutics' Price Target to $49 from $46, Keeps Outperform Rating	21-08-16	MT
SILVERBACK THERAPEUTICS : JonesTrading Starts Silverback Therapeutics at Buy With $50 Price Target	21-05-27	MT
SILVERBACK THERAPEUTICS : SVB Leerink Adjusts Price Target on Silverback Therapeutics to $46 From $49, Maintains Outperform Rating	21-05-24	MT